within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CA04_Dopamine;

model Dopamine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.0000000000000004e-05,
    adminDuration = 600,
    adminMass = 2.5 / 1000000,
    adminCount = 1,
    Vd = 0.00011,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00033600000000000004,
    k12 = 1.0333333333333333e-05,
    k21 = 1.0333333333333333e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dopamine</td></tr><tr><td>ATC code:</td><td>C01CA04</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>2.5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.11</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.8</td><td>L/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dopamine is an endogenous catecholamine neurotransmitter that acts as a nonselective agonist at dopamine, alpha, and beta adrenergic receptors. It is primarily used as a vasopressor and inotropic agent in the treatment of shock, particularly cardiogenic and septic shock, and sometimes in advanced heart failure. Dopamine is an approved drug used in clinical settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intravenous infusion.</p><h4>References</h4><ol><li><p>MacGregor, DA, et al., &amp; Scuderi, PE (2000). Pharmacokinetics of dopamine in healthy male subjects. <i>Anesthesiology</i> 92(2) 338–346. DOI:<a href=\"https://doi.org/10.1097/00000542-200002000-00013\">10.1097/00000542-200002000-00013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10691218/\">https://pubmed.ncbi.nlm.nih.gov/10691218</a></p></li><li><p>Banner, W, et al., &amp; Dean, JM (1991). Nonlinear dobutamine pharmacokinetics in a pediatric population. <i>Critical care medicine</i> 19(7) 871–873. DOI:<a href=\"https://doi.org/10.1097/00003246-199107000-00008\">10.1097/00003246-199107000-00008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2055074/\">https://pubmed.ncbi.nlm.nih.gov/2055074</a></p></li><li><p>Kwa, A, et al., &amp; Jelliffe, RW (2008). A population pharmacokinetic model of epidural lidocaine in geriatric patients: effects of low-dose dopamine. <i>Therapeutic drug monitoring</i> 30(3) 379–389. DOI:<a href=\"https://doi.org/10.1097/FTD.0b013e3181778fa3\">10.1097/FTD.0b013e3181778fa3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18520611/\">https://pubmed.ncbi.nlm.nih.gov/18520611</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C01CA04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dopamine;
